Theralase Technologies Inc. V.TLT

BMS to buy Turning Point Therapeutics for 4.1B$US

[ScienceFirst]

Another valuation example that fits the documented 2-10B$US range I often document.

This one is mostly NSCLC related.

Bristol Myers to buy Turning Point Therapeutics for 4.1B$US

Acquisition Brings Repotrectinib, a Potential Best-in-Class, Next-Generation ROS1/NTRK Inhibitor with Differentiates Duration of Response for Patients with ROS1-positive First-Line Non-Small Cell Lung Cancer (NSCLC); Expected to Launch in 2023

Bristol Myers Squibb to Commence All-Cash Tender Offer to Acquire All Outstanding Shares of Turning Point Therapeutics for $76.00 per Share (4.1B$US)

 June 3 (Reuters) - Bristol Myers Squibb (BMY.N)said on Friday it would acquire drug developer Turning Point Therapeutics Inc (TPTX.O) for $4.1 billion in cash to gain access to a portfolio of promising cancer drugs.

The U.S. drugmaker will pay $76 per Turning Point share, a 122.5% premium to its last closing price.

Turning Point's lead asset is repotrectiniba that belongs to a class of treatments called tyrosine kinase inhibitors.

[Lesalpes29]

Is this possible for a stock that I hold! Lol

[ScienceFirst]

4.1B$US for such a sall market of NSCLC! Repotrectinib is one of several molecules designed to treat cancers driven by ROS1-fusion mutations. Patients with ROS1 rearrangements, which are found in 1% to 2% of people with non-small cell lung cancer (NSCLC), are already served by Pfizer’s Xalkori and Roche’s Rozlytrek. Yet, Turning Point has spied an opportunity to muscle into the field

[thadeush]

$76/share...let me get my calculator...

[ScienceFirst]

Thadeush... It's never the share price $ that you have to focus on as companies all have different shares outstanding. You have to focus on the valuation (4.1B$US in this dxamol).  Then, you divide it by the number of shares (fully diluted) of TLT to assess what would have been our equivalent. As already documented many times, it always come back to a range of 2-10G$US for an oncology

[ScienceFirst]

4.1B$US for such a small market of NSCLC! Repotrectinib is one of several molecules designed to treat cancers driven by ROS1-fusion mutations. Patients with ROS1 rearrangements, which are found in 1% to 2% of people with non-small cell lung cancer (NSCLC), are already served by Pfizer’s Xalkori and Roche’s Rozlytrek. Yet, Turning Point has spied an opportunity to muscle into the

[Legit62]

Hopefully we will see that kind of money for our science. A buyout is easy, dont have to worry about selling shares, cash goes into account, wouldnt mind that is we get the right dollar amount

[Legit62]

ScienceFirst, what is our market compared to that company

[Rumpl3StiltSkin]

I am not Sf but I have some idea. I did a back of napkin estimate based off of the NMIBC growth expectation article that came out here on SH several years ago. Using just raw sales expectations and our float of ~290M Shares/Warrants/Options I came up with ~ $8 US per share using 16x sales. NOT EBITDA, just raw numbers. Just TLT's chunk of the NMIBC market of around 15-20%...  :-)

[Legit62]

Thats not a bad number, plus we have other indications in the works which could drive that higher

[LaserStock29]

Only get paid for the science that's matured and developed License out rights for other indications = bigger cash upfront NMIBC is probably 2b -3broughly for TLD 1433 Then licensing Ruthenium with ACT for the other indications by Dr.Kaspler 5 of em Lung, brain, head neck, cervical and colon. Get it done by 1Q 2023 and stop f'ing around

[Rumpl3StiltSkin]

Yep, not a bad number at all. If I can do a simple calculation, know Pharma can do even better number crunching. As can Kristina. And everyone knows NMIBC is just a small sliver of TLT's potential. I doubt we will get any less that $3B US as an early buyout offer. 

[Oilminerdeluxe]

Music to my ears.

[gojotv!]

Investors got $76US/share... That's below the range of what I'd accept for my TLT shares, but it does indicate potential value... I don't see letting go of my TLT shares for less than $150 per... After all, Apple only makes little sound and picture devices. It doesn't save lives! Thoughts?

[charlierock]

[aussyspitz]

Love the enthusiasm but don't perceive that as realistic. A 150 sp implies a nearly 44B mcap/buyout offer I.e. 291M fully diluted x $150 USD is approx 44B. I think realistically we get bought out early between 2B and 10B or approx 7 to 34 USD per share. Right now personally I would just like to see this break a $1 first then maybe I'll allow myself to dream of anything loftier.

[Legit62]

Would love to see a dollar, then $7 to $34 sounds great, just hope we dont sell out cheap

[Oilminerdeluxe]

Let's get the data up and/or to $-territory first. The numbers are  nice ones though.

[lesflics]

What would you like to be when you grow up?